Zinzani, P L <br/><br/>
Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle-cell lymphoma.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  Feb 2000 
 - 773-9 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>0732-183X 
<br/><br/><label>Standard No.: </label>10.1200/JCO.2000.18.4.773  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antibiotics, Antineoplastic--administration & dosage<br/>Antineoplastic Agents--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Chi-Square Distribution<br/>Disease Progression<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Idarubicin--administration & dosage<br/>Leukemia, Lymphocytic, Chronic, B-Cell--drug therapy<br/>Linear Models<br/>Lymphoma, Follicular--drug therapy<br/>Lymphoma, Mantle-Cell--drug therapy<br/>Male<br/>Middle Aged<br/>Neoplasm Staging<br/>Remission Induction<br/>Survival Rate<br/>Vidarabine--administration & dosage